Ascendis Pharma A/S (NASDAQ:ASND – Get Free Report) was upgraded by equities research analysts at Wedbush to a “strong-buy” rating in a note issued to investors on Monday, Zacks.com reports. Other equities analysts have also recently issued research reports about the stock. TD Cowen lifted their target price on shares of Ascendis Pharma A/S from […]